PP01.84 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Tae Min Kim, Valentina Guarneri,Pei Jye Voon, Boon Khaw Lim,Jin-ji Yang, Marie Wislez,Cheng Huang, Chong Kin Liam,Julien Mazieres, ye Mun Tho,Hidetoshi Hayashi, Nhung Nguyen,Puey Ling Chia,Filippo de Marinis,Jo Raskin,Qinghua Zhou,Giovanna Finocchiaro,Xiuning Le, Daniel Tan, Richard M. O’Hara Journal of Thoracic Oncology（2024）
AI 理解论文
溯源树
样例
